Iovance Shares Fall Premarket As FDA Places Study On Hold After Patient Death
27 12월 2023 - 9:54PM
Dow Jones News
By Colin Kellaher
Shares of Iovance Biotherapeutics tumbled in premarket trading
Wednesday after the biotechnology company said the U.S. Food and
Drug Administration placed a clinical hold on a Phase 2 study of
its LN-145 therapy in non-small cell lung cancer following the
death of a study patient.
Iovance shares, which closed Tuesday at $8.89, were recently
down 26% to $6.59 in premarket trading.
Iovance, which is studying LN-145 in certain patients with
advanced non-small cell lung cancer who have poor prognosis
following disease progression and limited treatment options, said
the fatality is potentially related to the study's
non-myeloablative lymphodepletion pre-conditioning regimen.
The San Carlos, Calif., company said it will pause enrollment
and the treatment regimen for new patients in the study during the
clinical hold, adding that the hold has no impact on any of its
other clinical trials.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 27, 2023 07:39 ET (12:39 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Iovance Biotherapeutics (NASDAQ:IOVA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
